|
Aloisi MS [41]
|
2002
|
1997–1999
|
Italy
|
Cohort
|
HIV-infected subjects who had never received antiretroviral therapy
|
DU
|
100
|
SR
|
6 months
|
Moderate
|
|
Avery AK [42]
|
2013
|
2008–2011
|
USA
|
Cross- sectional
|
Participants who were previously diagnosed HIV+
|
HL
|
90
|
SR
|
1 week
|
High
|
|
Biello KB [43]
|
2016
|
2012
|
Latin America
|
Cross- sectional
|
Men who have sex with men who reported being paid for sex with another man in the past year
|
SW
|
100
|
SR
|
1 month
|
Moderate
|
|
Bijker R [44]
|
2017
|
2007–2013
|
Asia
|
Cohort
|
HIV-infected adults starting first-line ART
|
DU
|
95
|
SR
|
6 months
|
High
|
|
Braitstein P [45]
|
2006
|
1996–2000
|
Canada
|
Cohort
|
Individuals used triple combination ART as their first HIV therapy and had documented HCV serology
|
DU
|
95
|
PR
|
1 year
|
High
|
|
Cohn SE [46]
|
2008
|
2002–2005
|
USA
|
Cohort
|
HIV-infected women between 20 and 34 weeks’ gestation
|
DU
|
100
|
SR
|
4 days or 3 months
|
Moderate
|
|
Cohn SE [47]
|
2011
|
1997–1999
|
USA
|
Cross- sectional
|
HIV-infected subjects without prior Mycobacterium avium complex (MAC) and with documented immune reconstitution
|
DU
|
100
|
SR
|
2 days
|
High
|
|
de Boni RB [48]
|
2016
|
2012–2013
|
Argentina, Brazil, Chile, Honduras, Mexico, and Peru
|
Cross- sectional
|
Individuals receiving care at HIV clinics
|
DU
|
100
|
SR
|
1 week
|
High
|
|
de Jong BC [49]
|
2005
|
2001
|
USA
|
Cross- sectional
|
Patients within a public health care system for HIV/AIDS
|
DU
|
100
|
SR
|
4 weeks
|
High
|
|
Duff PK [50]
|
2017
|
2014–2017
|
Canada
|
Cohort
|
Women living with HIV
|
DU
|
95
|
SR
|
3 to 4 weeks
|
High
|
|
Gebo KA [51]
|
2003
|
1999–2000
|
USA
|
Cross- sectional
|
Consecutive HIV-infected patients taking at least 1 antiretroviral medication
|
DU
|
90
|
SR
|
2 weeks
|
Moderate
|
|
Gordillo V [52]
|
1999
|
1997–1998
|
Spain
|
Cross- sectional
|
HIV-infected patients who were on treatment with antiretroviral drugs
|
DU
|
90
|
SR and pill count
|
1 week
|
High
|
|
Hicks PL [53]
|
2007
|
2003
|
USA
|
Cross- sectional
|
HIV patients on HAART in primary care
|
DU
|
95
|
SR
|
2 weeks
|
Moderate
|
|
Jin H [54]
|
2018
|
2013–2017
|
USA
|
Cross- sectional
|
HIV-positive men who have sex with men who had biologically confirmed, recent methamphetamine use
|
HL
|
90
|
SR
|
1 month
|
Moderate
|
|
Johnson MO [55]
|
2003
|
2000–2002
|
USA
|
Cross- sectional
|
HIV-positive adults taking ART
|
DU, HL
|
90
|
SR
|
3 days
|
Moderate
|
|
Joseph B [56]
|
2015
|
1996–2012
|
Canada
|
Cohort
|
HIV-infected people who use illicit drugs in a setting of universal no-cost HIV/AIDS treatment
|
HL, DU, SW
|
95
|
PR
|
6 months
|
High
|
|
King RM [57]
|
2012
|
2007–2009
|
USA
|
Cross- sectional
|
Persons living with HIV/AIDS who smoke
|
DU
|
100
|
SR
|
4 days
|
Moderate
|
|
Krusi A [58]
|
2010
|
1996–2007
|
Canada
|
Cohort
|
HIV-positive injection drug users
|
DU
|
95
|
PR
|
6 months
|
High
|
|
Mohanned H [59]
|
2004
|
1999–2001
|
USA
|
Cohort
|
Convenience sample of HIV-infected subjects seen at outpatient HIV clinics
|
DU
|
100
|
SR
|
1 week
|
High
|
|
O’Neil CR [60]
|
2012
|
2007–2010
|
Canada
|
Cohort
|
HIV-positive persons who have accessed antiretroviral therapy
|
DU
|
95
|
PR
|
1 year
|
High
|
|
Palepu A [61]
|
2004
|
1997–2002
|
Canada
|
Cohort
|
Participants who were HIV-infected, naive to HAART and who were prescribed treatment
|
DU
|
100
|
PR
|
6 months
|
High
|
|
Roux P [62]
|
2011
|
2006–2008
|
France
|
Cohort
|
HIV/HCV coinfected patients on ART
|
DU
|
100
|
SR
|
4 days
|
Moderate
|
|
Shannon K [63]
|
2005
|
2002–2004
|
Canada
|
Cohort
|
HIV-infected persons
|
DU
|
95
|
PR
|
6 months
|
Moderate
|
|
Sharpe TT [64]
|
2004
|
1997–2000
|
USA
|
Cross- sectional
|
HIV-infected women
|
DU
|
100
|
SR
|
not reported
|
Moderate
|
|
Stone VE [65]
|
2001
|
1993–1995
|
USA
|
Cross- sectional
|
Women living with HIV
|
DU
|
100
|
SR
|
3 days
|
Moderate
|
|
Teixeira C [66]
|
2013
|
2006–2008
|
Brazil
|
Cohort
|
HIV-positive patients with no previous ART
|
DU
|
95
|
SR
|
1 month
|
High
|
|
Tucker JS [67]
|
2003
|
1997–1998
|
USA
|
Cohort
|
People with known HIV infection and made at least one patient care visit
|
DU
|
100
|
SR
|
1 week
|
High
|
|
Turner BJ [68]
|
2000
|
1993–1997
|
USA
|
Cohort
|
Postpartum HIV-infected women
|
DU
|
80
|
PR
|
> 2 months
|
High
|
|
Wilson TE [69]
|
2002
|
1998–1999
|
USA
|
Cohort
|
HIV-positive women
|
DU
|
95
|
SR
|
6 months
|
Moderate
|
